+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 19Years +
All Genders
ID07431762

Safety Comparison of Aspirin and Warfarin for Six Months After Bioprosthetic Heart Valve Replacement

Led by Asan Medical Center · Updated on 2026-07-06

1058

Participants Needed

3

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial evaluates the safety of two oral antithrombotic therapies, aspirin and vitamin K antagonists warfarin, during the first six months after bioprosthetic heart valve replacement in the aortic or mitral positions. It is a multinational, multicenter, randomized, open-label, active-controlled study designed to compare these treatments in patients who have undergone tissue valve replacement surgery. Participants are randomly assigned to receive either aspirin at a dose of 100 mg once daily for six months or warfarin with a target International Normalized Ratio INR maintained between 2.0 and 3.0 for six months. The study focuses on the initial six-month period following valve replacement surgery to monitor treatment effects. Throughout the six months, participants will be monitored for a composite of clinical events including stroke, transient ischemic attack, systemic embolism, myocardial infarction, major bleeding, valve thrombosis, and all-cause mortality. These outcomes will be assessed to evaluate safety. Participants will follow a clinical schedule with regular follow-up visits as part of the study protocol.

CONDITIONS

Brief Title

Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprosthetic Heart Valve Replacement

Research Team

J

Joon-bum Kim, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here